Melinta reports Phase III success for antibiotic
This article was originally published in Scrip
Executive Summary
Connecticut-based Melinta Therapeutics says that a Phase III study of its lead product, the investigational fluoroquinalone antibiotic, delafloxacin IV has met its primary end point.
You may also be interested in...
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
The latest drug development news and highlights from our FDA Performance Tracker.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.